Inventor
TYSON KERRY LOUISE
GB39 patents
⚠️ This page may combine multiple inventors who share the name “TYSON KERRY LOUISE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UCB BIOPHARMA SPRL
13 patentsUS10590197B2Mar 17, 2020
Antibody molecules which bind CD22
UCB BIOPHARMA SPRL14 citations94
US9499603B2Nov 22, 2016
PD-1 antibodies
UCB BIOPHARMA SPRL19 citations92
US10370447B2Aug 6, 2019
Molecules with specificity for CD79 and CD22
UCB BIOPHARMA SPRL15 citations85
US10618957B2Apr 14, 2020
Antibody molecules which bind CD79
UCB BIOPHARMA SPRL9 citations84
US10233243B2Mar 19, 2019
Anti-FcRn antibodies
UCB BIOPHARMA SPRL10 citations82
US10273302B2Apr 30, 2019
Antibodies specific to FcRn
UCB BIOPHARMA SPRL5 citations81
US10774152B2Sep 15, 2020
Molecules with specificity for CD45 and CD79
UCB BIOPHARMA SPRL5 citations73
US11384148B2Jul 12, 2022
Anti-FcRn antibodies
UCB BIOPHARMA SPRL1 citations71
US10344081B2Jul 9, 2019
Tau-binding antibodies
UCB BIOPHARMA SPRL3 citations71
US9957320B2May 1, 2018
Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
UCB BIOPHARMA SPRL3 citations70
US11692041B2Jul 4, 2023
Antibody molecules which bind CD45
UCB BIOPHARMA SPRL0 citations62
US11220547B2Jan 11, 2022
Antibodies specific to FCRN
UCB BIOPHARMA SPRL0 citations60
US10766956B2Sep 8, 2020
Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
UCB BIOPHARMA SPRL1 citations54
UCB Biopharma SRL
11 patentsUS11472879B2Oct 18, 2022
Antibody molecules which bind CD22
UCB Biopharma SRL2 citations73
US11261252B2Mar 1, 2022
Molecules with specificity for CD79 and CD22
UCB Biopharma SRL2 citations73
US11261242B2Mar 1, 2022
Anti-alpha-synuclein antibodies
UCB Biopharma SRL3 citations71
US10906966B2Feb 2, 2021
Tau-binding antibodies
UCB Biopharma SRL1 citations71
US12331117B2Jun 17, 2025
Antibody molecules which bind CD22
UCB Biopharma SRL0 citations62
US12545720B2Feb 10, 2026
Anti-alpha-synuclein antibodies
UCB Biopharma SRL0 citations61
US12338285B2Jun 24, 2025
Anti-FcRn antibodies
UCB Biopharma SRL0 citations60
US11746145B2Sep 5, 2023
Tau-binding antibodies
UCB Biopharma SRL0 citations60
US12410244B2Sep 9, 2025
Anti-alpha-synuclein antibodies
UCB Biopharma SRL0 citations57
US11292831B2Apr 5, 2022
Anti-alpha synuclein antibodies
UCB Biopharma SRL1 citations57
US11518803B2Dec 6, 2022
Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
UCB Biopharma SRL0 citations54
UCB PHARMA SA
4 patentsUS8784823B2Jul 22, 2014
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
UCB PHARMA SA38 citations96
US9394361B2Jul 19, 2016
Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
UCB PHARMA SA4 citations70
US9321840B2Apr 26, 2016
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
UCB PHARMA SA2 citations61
US7273744B2Sep 25, 2007
Heparanase-like polypeptides
UCB PHARMA SA1 citations43
HARVARD COLLEGE
3 patentsUS12247068B2Mar 11, 2025
Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
HARVARD COLLEGE1 citations69
US10160798B2Dec 25, 2018
Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders
HARVARD COLLEGE4 citations68
US11014979B2May 25, 2021
Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
HARVARD COLLEGE4 citations67